Transarterial chemoembolization (TACE) using mitomycin and lipiodol with or without degradable starch microspheres for hepatocellular carcinoma: comparative study

• Published in: BMC cancer Vol. 18; no. 1; p. 188
• Main Authors: Gruber-Rouh, Tatjana, Schmitt, Cornelia, Naguib, Nagy N N, Nour-Eldin, N A, Eichler, Katrin, Beeres, Martin, Vogl, Thomas J
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 14.02.2018; BioMed Central; BMC
• Subjects: Antimitotic agents; Antineoplastic agents; Cancer; Care and treatment; Chemoembolization; Chemotherapy; Comparative analysis; Diagnosis; Dosage and administration; DSM; HCC; Hepatoma; Lipidol; Local control; Mitomycin; Survival data; HCC; Lipidol; Local control; Chemoembolization; DSM; Survival data
• ISSN: 1471-2407; 1471-2407
• DOI: 10.1186/s12885-018-4099-x

To evaluate survival data and local tumor control after transarterial chemoembolization in two groups with different embolization protocols for the treatment of HCC patients. Ninty-nine patients (mean age: 63.6 years), 78 male (78.8%) with HCC were repeatedly treated with chemoembolization in 4-week-intervals. Eighty-eight patients had BCLC-Stage-B and in 11 patients, chemoembolization was performed for bridging (BCLC-Stage-A). In total, 667 chemoembolization treatments were performed (mean 6.7 treatments/patient). The administered chemotherapeutic agent included mitomycin. For embolization, lipiodol only (n = 51;51.5%; mean age 63.8 years; 38 male), or lipiodol plus degradable starch microspheres (DSM) (n = 48; 48.5%; mean age 63.4 years; 40 male) were used. The local tumor response was assessed by MRI using Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1). Patient survival times were evaluated using Kaplan-Meier curves and log-rank tests. The local tumor control in the lipiodol-group was: PR (partial response) in 11 (21.6%), SD (stable disease) in 32 (62.7%) and PD (progressive disease) in 8 cases (15.7%). In the lipiodol-DSM-group, PR was seen in 14 (29.2%), SD in 22 (45.8%), and PD in 12 (25.0%) individuals (p = 0.211). The median survival of patients after chemoembolization with lipiodol was 25 months and in the lipiodol-DSM-group 28 months (p = 0.845). Our data suggest a slight benefit of the use of lipiodol and DSM in comparison of using lipiodol only for chemoembolization of HCC in terms of local tumor control and survival data, this trend did not reach the level of significance.